Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06610734 2026-02-09

SKY

Phase 2 Recruiting

202 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT07385989 2026-02-04

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

Phase 2 Not yet recruiting

40 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05621707 2026-02-02

RICE

Phase 2 Active not recruiting

50 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06710847 2026-02-02

SYLVER

Phase 1/2 Active not recruiting

14 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

318 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07363369 2026-01-23

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Phase 1 Not yet recruiting

10 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07364305 2026-01-23

Lalo

Phase 2 Recruiting

50 enrolled

ICC

NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Phase 1 Recruiting

25 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT06190275 2026-01-21

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Phase NA Recruiting

12 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Phase 2 Recruiting

30 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07349836 2026-01-20

Application of mRNA Immunotherapy Technology in EB Virus Related Diseases

Phase EARLY_PHASE1 Not yet recruiting

40 enrolled

EBV-associated Tumors

Clinical Trials

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

INS-ESCC-CT

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

TORCH-iTNT

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

TRIUNITE-08

Priming Immunotherapy in Advanced Disease With Radiation

DOMISOL

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

CIML NK Cell in Head & Neck Cancer

JACKPOT38

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

PRISM-TNBC

MINER2

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

MINER

iFOCUS

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

SKY

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

RICE

SYLVER

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Lalo

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Application of mRNA Immunotherapy Technology in EB Virus Related Diseases